Tango Therapeutics Stock Extends Rally to 57% as Mizuho Hikes Price Target

Reflecting the growing optimism surrounding biotechnology innovations, Tango Therapeutics announced exceptional clinical results for its advanced pancreatic cancer treatment. The Phase 1/2 trial demonstrated a 92% objective response rate, with a 90% progression-free survival rate at six months. Following these findings, the stock extended its rally to close with a 57.22% gain at $28.68, marking a new 52-week high.

This breakthrough comes as the healthcare sector sees intense competition in developing treatments for solid tumors, prompting Mizuho Securities to raise its price target for the stock to $36.00, bringing the company's market capitalization to approximately $3.69 billion. Tango's results appear superior to historical data from peers like Mirati Therapeutics, which was acquired by Bristol Myers Squibb last year for $4.8 billion according to Reuters reports, bolstering the firm's standing among mid-cap biotech peers.

Investors should watch for price momentum sustainability following the stock's close at $28.68 on June 8, 2026, as it approaches the new $36.00 target. Looking ahead, broader market sentiment in the growth sector may be influenced by upcoming Federal Reserve speeches from officials Kashkari and Hammack in June 2026, which will dictate risk appetite for high-growth biotech equities.